Last reviewed · How we verify

CHG 2% w/v and IPA 70% v/v

Johns Hopkins University · FDA-approved active Small molecule

CHG 2% w/v and IPA 70% v/v is a Topical antiseptic/antimicrobial combination Small molecule drug developed by Johns Hopkins University. It is currently FDA-approved for Skin antisepsis and preoperative skin preparation, Prevention of surgical site infections, Skin disinfection and hygiene. Also known as: Chloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA).

Chlorhexidine gluconate (CHG) and isopropyl alcohol (IPA) work synergistically to rapidly kill bacteria and other microorganisms on skin through disruption of cell membranes and protein denaturation.

Chlorhexidine gluconate (CHG) and isopropyl alcohol (IPA) work synergistically to rapidly kill bacteria and other microorganisms on skin through disruption of cell membranes and protein denaturation. Used for Skin antisepsis and preoperative skin preparation, Prevention of surgical site infections, Skin disinfection and hygiene.

At a glance

Generic nameCHG 2% w/v and IPA 70% v/v
Also known asChloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA)
SponsorJohns Hopkins University
Drug classTopical antiseptic/antimicrobial combination
ModalitySmall molecule
Therapeutic areaInfection Prevention / Dermatology
PhaseFDA-approved

Mechanism of action

CHG is a broad-spectrum antimicrobial that binds to and disrupts bacterial cell membranes, while IPA acts as a rapid-acting antiseptic that denatures proteins and evaporates quickly. Together, the 2% CHG and 70% IPA formulation provides both immediate antimicrobial activity and sustained residual protection, making it effective for skin antisepsis and disinfection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CHG 2% w/v and IPA 70% v/v

What is CHG 2% w/v and IPA 70% v/v?

CHG 2% w/v and IPA 70% v/v is a Topical antiseptic/antimicrobial combination drug developed by Johns Hopkins University, indicated for Skin antisepsis and preoperative skin preparation, Prevention of surgical site infections, Skin disinfection and hygiene.

How does CHG 2% w/v and IPA 70% v/v work?

Chlorhexidine gluconate (CHG) and isopropyl alcohol (IPA) work synergistically to rapidly kill bacteria and other microorganisms on skin through disruption of cell membranes and protein denaturation.

What is CHG 2% w/v and IPA 70% v/v used for?

CHG 2% w/v and IPA 70% v/v is indicated for Skin antisepsis and preoperative skin preparation, Prevention of surgical site infections, Skin disinfection and hygiene.

Who makes CHG 2% w/v and IPA 70% v/v?

CHG 2% w/v and IPA 70% v/v is developed and marketed by Johns Hopkins University (see full Johns Hopkins University pipeline at /company/johns-hopkins-university).

Is CHG 2% w/v and IPA 70% v/v also known as anything else?

CHG 2% w/v and IPA 70% v/v is also known as Chloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA).

What drug class is CHG 2% w/v and IPA 70% v/v in?

CHG 2% w/v and IPA 70% v/v belongs to the Topical antiseptic/antimicrobial combination class. See all Topical antiseptic/antimicrobial combination drugs at /class/topical-antiseptic-antimicrobial-combination.

What development phase is CHG 2% w/v and IPA 70% v/v in?

CHG 2% w/v and IPA 70% v/v is FDA-approved (marketed).

What are the side effects of CHG 2% w/v and IPA 70% v/v?

Common side effects of CHG 2% w/v and IPA 70% v/v include Skin irritation or erythema, Contact dermatitis, Allergic reaction (rare).

Related